Article Details

Cancer biotech ArriVent Biopharma files for a $100 million IPO - Renaissance Capital

Retrieved on: 2024-01-06 09:46:39

Tags for this article:

Click the tags to see associated articles and topics

Cancer biotech ArriVent Biopharma files for a $100 million IPO - Renaissance Capital. View article details on hiswai:

Excerpt

Goldman Sachs, Jefferies, and Citi are the joint bookrunners on the deal. No pricing terms were disclosed. Relevant Profile: AVBP. IPO Pro ...

Article found on: www.renaissancecapital.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo